First released in 2004, the Guide is a joint publication of CITC and the Tuberculosis Control Branch of the California Department of Public Health. It contains information and user-friendly tools and templates for use by any clinician who participates in the management of patients with drug-resistant TB. The 10 chapters and 4 appendices cover major topics pertaining to epidemiology, diagnosis, laboratory issues, treatment, medications, pediatrics, co-morbidities and special situations, monitoring and case management, adverse reactions, and treatment of contacts.
View online or download PDF.
What's new in the third edition of the Guide?
- Laboratory, a new chapter presenting information about the laboratory tests used to confirm TB infection and/or disease, including tests available for the more rapid molecular detection of TB and drug resistance
- New data on outcomes of treatment for drug-resistant TB and newer drugs and regimens available
- Updated information about 23 medications used to treat tuberculosis, including 5 new fact sheets not included in the second edition: Bedaquiline, Clarithromycin, Delamanid, Meropenem, and Rifapentine.
- Expanded information about diagnosing and treating TB disease and LTBI in children, now devoted to its own chapter
- New sections on “Diabetes Mellitus” and “Solid Organ Transplant” in Chapter 7, Co-Morbidities and Special Situations
- Updated listings of resources in the Appendices.